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                   SPUTUM STATUS OF SPUTUM POSITIVE PULMONARY       
TUBERCULOSIS PATIENTS WHO HAVE COMPLETED CATEGORY I ATT  
                                   UNDER DOTS TREATMENT 
 
BACKGROUND: DOTS remains the cornerstone in global efforts towards tuberculosis 
control. In India DOTS based guidelines given by RNTCP remains the standard of care for 
treatment of tuberculosis. New smear positive patients treated under RNTCP programme 
have a cure rate of 88% on completing treatment.  
AIMS & OBJECTIVES: To assess the bacteriological status of patients after one year of 
completion of primary chemotherapy under new smear positive category in RNTCP. To 
assess the effectiveness of cure obtained in that regimen and factors associated with 
increased chance of relapse. 
METHODS: The study is a prospective study. New smear positive patients who have 
registered under DOTS programme in the period October 2011 to March 2012 and declared 
cured are selected in two zones around Stanley medical college. Patients with 
immunosuppressive illness were excluded from the study. Their current sputum 
bacteriological status is assessed by sputum smear examination and culture in a spot 
sputum specimen. Risk factors associated with relapse are also evaluated by means of 
questionnaire, clinical examination, biochemical test, radiological assessment. Patients who 
are bacteriologic ally active were started on category II as per RNTCP norms. The sampling 
method is non probability sampling-convenient sampling.  Radiological assessment intended 
in the protocol was not done during the study. 
RESULTS: Sputum AFB culture of the 49 patients showed positive culture in three patients. . 
The relapse of pulmonary TB among patients who have completed ATT under RNTCP is 6 % 
at the end of one year. One out of three patients revealed SH resistance. 
CONCLUSION: Evaluation of primary resistance prior to treatment may help in avoiding 
future relapses. 
KEY WORDS: Tuberculosis, New smear positive, Relapse, DOTS, RNTCP, AFB, ATT. 
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INTRODUCTION 
 
New sputum positive pulmonary tuberculosis  patients  are started 
on category I Anti Tuberculosis Treatment (ATT) under DOTS. New 
smear positive patients are treated with a 6 month regimen. In the first 
two months called the intensive phase patients are treated with four 
drugs that include rifampicin(R), isoniazid (H), pyrazinamide (Z) and 
Ethambutol (E). Intensive phase is followed by continuation phase in 
which only isoniazid and rifampicin is taken for four months. In both the 
phases drugs are given three days in a week called intermittent regimen. 
        The primary goals of treatment of sputum positive pulmonary 
tuberculosis patients are to kill tubercle bacilli rapidly, prevent the 
emergence of drug resistance and eliminate the persistent bacilli from 
the host’s tissues to prevent relapse (1). Patients started on ATT usually 
become sputum negative at the end of 2 to 3 months (80% -90%). At the 
end of 6 months of category I the cure rate achieved among new smear 
positive patients is 88% (2). The data about relapses that occur from this 
88% is lacking. Those patients who report spontaneously to the health 
sector and found to have relapsed are put on category II regimen. The 
present study is to determine how many of these patients who have been 
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cured with category I under programme conditions are able to maintain 
their bacteriological negativity at the end of one year period .From the 
earlier studies it has been found that most of the relapses occur within 
one year of completion of primary chemotherapy. Hence a cohort of 
patients who have completed or cured from their smear positive status 
and completed one year post treatment status are included in the study. 
In these patients sputum smear examination and culture for acid fast 
bacilli are done to look for bacteriological activity. 
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AIM OF THE STUDY 
 
To identify patients who are bacteriologically active one year 
after completion of their primary chemotherapy.   
OBJECTIVES OF THE STUDY 
1) To assess the effectiveness of cure obtained from category I 
regimen under programme conditions. 
2) To assess presence of co morbid illnesses and other risk factors as 
a causative or helping factor in the development of relapse. 
3) Whether drug resistance has any role causing relapse. 
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REVIEW OF LITERATURE 
 
INTRODUCTION  
Tuberculosis is caused by bacillus Mycobacterium tuberculosis. It 
continues to be a major health challenge that the global community is 
facing. Currently it is the second major cause of mortality due to 
infectious agent superseded only by Human Immunodeficiency Virus (2). 
Infection mainly affects the lung (pulmonary). It can also affect the 
extra pulmonary sites. The great burden of tuberculosis in developing 
world is in the active age group 15 to 60 years of age (3).       
EVOLUTION OF TUBERCULOSIS TREATMENT 
Tuberculosis control measures were started as a global measure. 
Cure of the sputum positive pulmonary tuberculosis patients is the only 
effective way in which spread of tuberculosis in the community can be 
controlled(5). Drugs effective against tuberculosis became available in 
1944 after the discovery of streptomycin when it was isolated from 
Streptomyces griseus by Waksman. Initially streptomycin monotherapy 
was used. It resulted in emergence of drug resistance and treatment 
failure. P- Amino salicylic acid was discovered in1949. It was found 
that when PAS given along with streptomycin prevented the emergence 
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of drug resistance. Isoniazid was discovered in 1952. Because of its low 
toxicity, high effectiveness and low cost it got incorporated into all 
primary regimen since then. Till these times treatment of tuberculosis 
was predominantly sanatorium based. In 1956 from trials in Madras it 
was demonstrated that ambulatory and domiciliary care was equally 
effective in treatment of tuberculosis. It was demonstrated that 
domiciliary care did not increase the chance of family members getting 
affected by tuberculosis. The most effective drug against tuberculosis 
rifampicin became available in 1960. It was observed that even with 
good health education patients did not take drugs regularly and this lead 
to the development of drug resistance so directly observed treatment 
was recommended as the standard of care in tuberculosis treatment. 
Intermittent regimen was demonstrated to be as effective as daily 
regimen in the treatment of tuberculosis in1964. Various trials around 
the world demonstrated that 6 to 8 months of treatment with 
combination of drugs were highly effective in treatment of tuberculosis. 
It was shown that even in smear positive severe cavitatory lung lesion 
addition of rifampicin decreased the duration of treatment with less 
relapse rate. Addition of pyrazinamide during the intensive phase of 
treatment was found to decrease the duration of treatment to 6 to 8 
months.  In  1980  regimens  were  tried  with  duration  of  treatment  less  
6 
than 6 months. All these regimens were associated with a high relapse 
rate and hence were discontinued.   
SCIENTIFIC BASIS IN THE EVOLUTION OF TUBERCULOSIS 
TREATMENT 
Mycobacterium tuberculosis is slow growing aerobic bacteria. Its 
doubling time is 18 hours and can remain dormant for a long time. In a 
pulmonary lesion due to tuberculosis there will be a large number of 
bacilli in rapidly dividing state (in a cavitatory lesion it is 108 & in case 
of a nodular lesion without a communicating bronchus it is 102 (10) and 
there will be a bacilli population with a slow metabolic rate. The chance 
of having drug resistant bacilli is more when the bacilli load is very high 
even before initiation of treatment.  
The chance of a drug sensitive bacilli to survive and remain latent 
even in the presence of adequate concentration of potent drugs like 
isoniazid and streptomycin is also there if the bacilli have a slow 
metabolic rate. Only drugs like rifampicin and pyrazinamide are 
effective against these slow multipliers. Regimens used to treat 
tuberculosis should contain at least 2 drugs for which the organism is 
susceptible and usually the patients are treated with four drugs during 
the intensive phase to avoid the emergence of drug resistance (6) 
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DIRECTLY OBSERVED TREATMENT SHORT COURSE  
With the advent of potent drugs the duration of therapy decreased. 
Pyrazinamide availability decreased the duration of treatment from 8 
months to six months. It was found that instead of daily regimen twice 
weekly or thrice weekly intake of drugs were also equally effective. 
These observations made the world health organisation to recommend 
that DOTS therapy should be the basis of treatment in tuberculosis 
patients. In DOTS during the intermittent therapy the drugs should be 
taken under the supervision of a health care personnel.   
            Before the introduction of Directly Observed Treatment Short 
course by WHO treatment regimens were chaotic and were not 
standardised. Treatment was not properly monitored. So treatment of 
sputum positive patients failed to make any impact on the incidence of 
tuberculosis in the community. Post introduction of DOTS most 
countries adopted it and regimens used against tuberculosis were 
uniform. These measures resulted in the better outcome of treatment. 
Today relapse, default, treatment failure have come down because of the 
monitored treatment under DOTS. Because of better treatment of 
sputum positive patients, incidence of tuberculosis has started to come 
down.  
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The DOTS strategy assures a compulsory and free availability of 
good quality drugs to all tuberculosis patients and necessitates drug 
administration under direct supervision, thereby ensuring the requisite 
regimen compliance(7) 
After the introduction of DOTS the incidences of tuberculosis 
have come down. WHO launched its next programme against 
tuberculosis “The Stop TB strategy”. 
The components of Stop TB Strategy are, 
x Pursue high quality DOTS expansion and enhancement. 
x Address TB/HIV, MDR-TB, and the needs of poor and vulnerable 
populations. 
x Contribute to health system strengthening based on primary 
health care. 
x Engage all care providers. 
x Empower people with TB, and communities through partnership. 
x Enable and promote research. 
The Stop TB Strategy has the following end points 
Vision: TB free world 
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Goal: to dramatically reduce the global burden of TB by 2015 in line 
with the Millennium Development Goals (MDGs) and the Stop TB 
Partnership  targets.  
Objectives 
x Achieves universal access to high quality care for all people with 
TB 
x Reduce the human suffering and socioeconomic burden 
associated with TB 
x Protect vulnerable  population from TB, TB/HIV and drug 
resistant TB 
x Support development of new tools and enable the timely and 
effective use. 
x Protect and promote human rights in TB prevention, care and 
control 
Targets: MDG 6, Target 6.c; Halt and begin to reverse the incidence of 
TB by 2015. 
x 2012: Reduce prevalence of and death due to TB by 50% 
compared with a baseline of 1990. 
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x 2050: eliminate TB as a public health problem (defined as <1 case 
per 1 million population per year) 
Currently incidence of tuberculosis is coming down at rate of 2% 
per year. Global incidence of tuberculosis in 2012 is 8.6 million cases. 
Mortality due to tuberculosis in the same year is 1.3 million cases. In 
developed world incidence initially was controlled but now with 
emergence of HIV incidence of tuberculosis in the developed world 
started increasing. Among the 8.6 million TB patients 13% were HIV 
positive.  
TUBERCULOSIS CONTROL IN INDIA 
Before the recommendation of DOTS by WHO tuberculosis 
treatment evolved in India from a predominantly sanatorium based 
therapy to a domiciliary care. In 1962 the National Tuberculosis control 
programme (NTP) was implemented. After in practice for more than 
three decades it was observed that drug adherence was still a major 
problem. In 1992 after a comprehensive review of tuberculosis control 
programme in India it was found that less than half of the patients with 
tuberculosis received accurate diagnosis and less  than half were 
effectively treated. Several factors lead to the failure of NTP. They 
were,  
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x Under utilization of laboratory services 
x Unnecessarily complicated treatment regimens 
x Shortage of drugs 
x Treatment completion was not assessed systematically. 
These factors that lead to the failure of NTP was analysed in 
detail and Revised National Tuberculosis Control Programme was 
introduced in 1993. In 2006, 100 % national coverage was achieved 
under RNTCP.RNTCP was based on DOTS recommended by WHO.  
 
12 
REVISED NATIONAL TUBERCULOSIS CONTROL 
PROGRAMME 
India has one fifth of world tuberculosis patients. India has the 
largest tuberculosis load more than any other country. India accounts for 
26% of world tuberculosis load. The prevalence of tuberculosis in India 
is 2.8 million cases. The incidence of tuberculosis is 2.2 million cases. 
Incidence among HIV positive patients is 0.13 million. Mortality due to 
tuberculosis  in  India  is  0.39  million.  The  largest  impact  is  in  the  age  
group 15 -60 years. This is found due to socioeconomic factors and the 
dependence of members of the family over this age group for earning 
and the exposure the age group receive in the community (26). In India 
DOTS was adopted under Revised National Tuberculosis Control 
Programme in 1993.Objective of RNTCP is to detect at least 70 percent 
of new smear positive patients and to cure at least 85 percent of those 
new smear positive patients. 
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The Revised national tuberculosis control programme has 
improved case finding facilities, made available short course 
chemotherapy in an un interrupted manner, increased the cure rates, and 
has provided data on adherence and outcome. 
Guidelines for treatment of tuberculosis were revised in 2010 by 
WHO. In a departure from the previous recommendations the WHO has 
now said that daily regimen is the preferred dosing regimen compared to 
the intermittent. Regimen (37). In RNTCP still intermittent regimen is 
used .A study done by Tuberculosis Research Centre in 1997 showed 
that twice as many patients on intermittent regimens relapsed compared 
with  those  on  daily  regimen(10%  Vs  5  %)(40). Although the 
bacteriological care was comparable in the two groups, the fully 
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intermittent therapy group had higher relapse rates. In a systematic 
review of 20 published trials it was concluded that the risk of relapse is 
related  to  the  total  dose  of  administered  and   the  relapse  rate  remains  
within acceptable limit of 5 % only with either daily regimen or 
regimens that incorporate a daily regimen in the intensive phase(42). 
Daily regimen showed a higher percentage of culture negativity at 2 
months and less unfavourable outcomes (relapse, death) at 12 months(43). 
        In current RNTCP guidelines new smear positive patients are 
treated with a 6 month regimen. In the first two months called the 
intensive phase patients are treated with four drugs that include 
rifampicin(R), isoniazid (H), pyrazinamide (Z) and Ethambutol (E). 
Intensive phase is followed by continuation phase in which only 
isoniazid and rifampicin is taken for four months. It is recommended 
that the 2HRZE/ 6HE regimen previously used to be phased out since it 
is associated with more relapse and death than 2HRZE/4HR. A 12 
month regimen is advised for TB meningitis in which ethambutol is 
replaced by streptomycin. For bone and joint TB the recommended 
regimen is for 9 months. 
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REGIMEN FOR TREATMENT OF TUBERCULOSIS (4) 
Category of cases    Intensive Phase     Continuation Phase 
New cases       2 month of HRZE      4 month of HR 
Previously treated cases 
Failure cases        Empirical MDR regimen       18-24 months 
Relapse/Default  
cases              2HRZES/1 HRZE/5HRE    
                            Regimen to be modified after DST        
 
RNTCP Recommendation(7)  
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WHO ESTIMATED BURDEN OF TUBERCULOSIS IN INDIA, 
2011 
 Number (Millions) 
(95% CI) 
Rate Per 100,000 
Persons (95% CI) 
Incidence 2.3 (2.0–2.5) 185 (167–205) 
Prevalence 3.1 (2.0–4.6) 256 (161–373) 
Mortality 0.32 (0.21–0.47) 26 (17–39) 
 Number (Millions) 
(95% CI) 
Percent 
(95% CI) 
HIV among estimated 
incident TB patients 
0.11 (0.075–0.16) 5% (3.3–7.1%) 
MDR-TB among 
notified pulmonary TB 
patients 
0.064 (0.044–0.075) 5.3% (3.6–6.2%) 
 
Notified New 
pulmonary TB patients 
0.021 (0.015–0.027) 2.1% (1.5–2.7%) 
 
Notified Re-treatment 
pulmonary TB patients 
0.043 (0.039–0.048) 15% (13–17%) 
 
 
ANTI TUBERCULOSIS DRUGS  
ISONIAZID  
         Isoniazid is a hydrazide of isonicotinic acid. It was first 
synthesized in Prague in 1912. It’s effectiveness in treating tuberculosis 
was demonstrated in 1952. It is effective only against tuberculosis and 
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not against any other organism. One of the most powerful anti 
tuberculosis drug that is active against both intracellular and 
extracellular bacilli. More marked action is seen in rapidly dividing 
organisms and less activity is seen against slow multipliers. It easily 
penetrates the cell membrane and it is widely distributed among body 
fluids with good CNS penetration.  
Peak drug concentration of INH is more important than sustained 
blood levels of the drug so single dose on a day is preferred rather than 
divided doses(17).  It’s a potent drug with less toxicity and available at a 
low cost. It’s also used in the treatment of latent tuberculosis and in 
chemo prophylaxis of tuberculosis.  
Use of INH is associated with peripheral neuropathy, blood 
dyscrasias, hyperglycaemia and liver damage more so in slow 
acetylators. Infrequently it is associated with psychosis and generalized 
epileptic convulsions. Both these complications can occur in any patient 
irrespective of their acetylator status. Peripheral neuropathy is the most 
common toxic manifestation. In HIV co infected patients the chance of 
having peripheral neuropathy is high. The frequency of developing 
peripheral neuropathy increases with dose of INH. Peripheral 
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neuropathy is more common in diabetics, chronic kidney disease 
patients, malnourished patients, alcoholics and slow acetylators.  
To prevent peripheral neuropathy pyridoxine (10-20 mg daily) 
can be added to regimen. High doses of pyridoxine should be avoided as 
it may reduce the effectiveness of isoniazid (18). INH induced 
hepatotoxicity is more common in those more than 35 years of age. It 
can be reversed if drug is discontinued early but fatal hepatotoxicity can 
occur (19, 20).  
RIFAMPICIN 
Rifampicin is a semisynthetic antibiotic. It was introduced in 
1965. It was found that the non toxic oral dose of rifampicin produces 
serum concentration that was 100 times more than the dose needed to 
inhibit the growth of tubercle bacilli. This led to trials that it can be used 
to reduce the duration of treatment (21). It became the single most 
important drug in the short course regimen. Bactericidal drug that is 
active against dormant bacteria. It is usually taken one hour before food 
or 2 hours after food since food reduce rifampicin absorption. It is 
associated with gastritis, purpura, thrombocytopenia and nephrotoxicity. 
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  Dose of rifampicin used is 10 mg/kg with a maximum dose of 
600mg. it can cause orange -red discolouration of body fluids. Usually 
given as 450 mg. Of patients weigh more than 60 kg it is 600 mg. 
Rifampicin produces more adverse reactions with intermittent 
regimen than daily regimen. It rarely causes cholestatic liver injury. Flu 
like syndrome is observed only with intermittent regimen (22). If a patient 
with rifampicin develops shock, renal failure, purpura or acute 
haemolytic reaction the drug need to be stopped and never be used 
again. Minor adverse effects were to be avoided patient should be on 
more frequent dosages than intermittent regimen and drug dose can be 
reduced.  
Rifampicin has a number of drug interactions because of the fact 
that it induces hepatic cytochrome oxidase. Rifabutin is a long acting 
congener that affects enzymes less (28,30). Rifapentene is longer acting 
drug with similar activity against M.tuberculosis  (29,30). 
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STREPTOMYCIN 
It was isolated by Waksman. Bactericidal drug that is active on 
rapidly dividing bacteria. It acts on extracellular bacilli. It doesn’t 
penetrate  cell  wall.  It  is  given  in  a  dose  of  0.75g  and  if  the  patient  
weight is less than 35 kg 0.5g is used. If age is more than 50 years only 
0.5g is used. It causes predominantly vestibular damage rather than 
deafness. Risk increases with dose and age of the patient. It occur more 
in patients with age more than 40 years. Vestibular damage presents 
with vertigo, ataxia, tinnitus and loss of hearing. 
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Once patient reports symptoms suggestive of vestibular damage 
drug dosage is reduced or drug is stopped. If treatment is continued it 
may result in permanent damage more so in patients with renal damage. 
Renal damage can also occur. It is avoided in patients with myasthenia 
gravis since it can affect neuromuscular conduction. It is contraindicated 
in pregnancy as it can cause fetal eighth nerve damage. 
PYRAZINAMIDE 
Primarily it acts on slow-multiplying bacilli and it augments the 
action of rifampicin. It helped in reduction of the duration of treatment 
(27). Dosage is 35 mg/kg body weight. It is associated with 
hepatotoxicity and hyperuricemia. Asymptomatic increase in uric acid is 
seen in many patients but symptomatic gout is rare. Hepatotoxicity is 
rare when used without rifampicin. But used along with rifampicin, 
chance of developing hepatotoxicity is high 
ETHAMBUTAOL 
Among the first line drugs it is the only bacteriostatic drug. It is a 
synthetic drug. It is associated with retro bulbar neuritis. It produces 
impaired vision with decrease in visual acquity and red-green colour 
blindness. Ocular toxicity is dose dependent. Rarely occur if less than 
15mg/kg is given daily(24,25). Not used in young children as they cannot 
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report visual disturbance. Visual disturbance improves if the drug is 
stopped or dosage is reduced before permanent damage occurs. Dosage 
used is 30 mg/kg in intermittent regimen.   
RANKING OF DRUGS WITH RESPECT TO THEIR TYPE OF 
ACTIVITY  
Drugs Early 
bactericidal 
Sterilizing 
activity 
Prevention of 
emergence of 
drug resistance 
Isoniazid  ++++ ++ ++++ 
Rifampicin +++ ++++ +++ 
Streptomycin +++ - ++ 
Pyrazinamide ++ +++ + 
Ethambutol + - ++ 
 
TREATMENT OUTCOME IN RNTCP  
Patient treated under RNTCP are categorised under the following 
at the end of treatment or during the course of treatment 
Cured 
Initially sputum smear –positive patient who has completed 
treatment and had negative sputum smears on two occasions, one of 
which was at the end of the treatment. 
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Treatment completed 
Initially sputum smear -positive patient who has completed 
treatment with negative smears at the end of the intensive phase/two 
months in the continuation phase, but none at the end of the treatment is 
declared as treatment completed. Or initially sputum smear negative 
patient who has received full course of treatment and has not become 
smear-positive at the end of treatment 
Treatment Failure 
Any TB patient who remains smear positive 5 months or more 
after initiation of the treatment and not put on MDR-TB treatment. 
Defaulted 
A patient after treatment initiation has interrupted treatment for 2 
consecutive months or more. 
Relapse 
A tuberculosis patient who was declared cured or treatment 
completed by a physician and who reports back to health facility and is 
now found to be sputum smear –positive. 
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The  definition  of  cure  in  the  RNTCP  is  a  negative  smear  
examination which has its own limitations, as bacillary counts< 10,000 
organisms/ml in sputum can be smear negative (38). 
TREATMENT OUTOMES 
6.1 million TB cases were notified to WHO in 2012. Among them 
5.7 million cases were newly diagnosed cases. 0.4 Million cases were 
previously diagnosed cases. India and China together account for 39% 
of the notified cases. 87% of the new cases are treated successfully. 87% 
of new smear positive patients are treated successfully. 56 Million 
Patients have been treated successfully since introduction of DOTS 
saving 22 million lives. 
          In India the percentage of retreatment case is high when compared 
to other countries. The causes for retreatment of patients are defaulter, 
failure of treatment and relapse. Relapse rate in India is almost 10 % 
which is much higher than the relapse rate in most countries. Most of 
the relapse in India is due to drug irregularity, initial drug resistance, 
alcohol and smoking (12). The percentage of retreatment smear positive 
cases among all smear positive patients is 24 % (under RNTCP) (11).In 
patients registered for CAT I ATT the rate of default is 12% and rate of 
treatment failure is 5%(15) . In one study reported by Thomas the relapse 
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rate was as high as 12.3% (12). Relapse rate in international studies were 
found to be 3.3% (13).  50  %  of  relapses  were  found  to  occur  in  first  6  
months (15). 68.5% of relapses were found to occur in the first 1 year. 
The median interval between declaring cure and relapse was found to be 
212 days (7 months). Among relapse cases the incidence of drug 
resistance was found to be 20% (12). The outcome of treatment of relapse 
cases were better than treatment of default and failure cases but less 
effective  when compared to new smear positive cases. 76.4% of relapse 
cases treated had positive outcome. The outcome of treatment failure 
cases was 53.85% and for default cases were 55.85% (16). 
RELAPSE OF TUBERCULOSIS 
In tuberculosis the time interval between the infection and disease 
manifestation is highly variable from a few weeks to even years. So 
development of active pulmonary tuberculosis in a patient previously 
treated for pulmonary tuberculosis may be because of activation of the 
previous infection or a reinfection by a fresh strain of Mycobacterium 
tuberculosis (33, 34). Activation of latent tuberculosis occurs when 
immunity of the patient decreases because of concurrent illness or if 
immunity is modified by drugs.  
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To differentiate between endogenous reactivation and exogenous 
reinfection DNA finger printing is needed. Restriction fragment length 
polymorphism is used to differentiate relapse of tuberculosis from 
reinfection from a different strain of Mycobacterium.  
Distinguishing between endogenous reactivation and exogenous 
reinfection is important because, 
¾ If reinfection is common in the population then isoniazid drug 
prophylaxis in a previously treated patient following an exposure 
to active pulmonary tuberculosis may be prudent. 
¾ If reinfection is common in the community then a new drug or 
drug regimen may not be judged properly in the community. 
¾ Natural infection will not give protection if reinfection is common 
in the community. Vaccine production for tuberculosis will be 
affected because of this(32).  
TO DIFFERENTIATE REINFECTION FROM 
REACTIVEATION 
Restriction length polymorphism is used in differentiating 
reinfection from reactivation of tuberculosis by the following two 
methods (35,36). 
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¾ If the strain of the initial infection is known then the RFLP of the 
current strain can be done and compared. 
¾ If the initial strain is not known RFLP is done for patients who 
come with relapse from the same community. If two or more 
patients have a same strain then they are said to be a cluster. If in 
the  same  community  another  relapse  patient  RFLP  is  of  a  
different pattern then he is said to have a endogenous reactivation.   
Restriction Fragment Length polymorphism 
 
Restriction Fragment length polymorphism pattern of the pre- and 
post treatment isolates. lane 1 and 2 shows the pre and post treatment 
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isolate of a patient and lane 3 and 4 shows the pre and post treatment of 
the next patient and so on.  
Most  of  the  relapses  that  occur  were  found  to  occur  during  the  
first 6 months following treatment with ATT. The rate of relapse comes 
down as the time after completion of treatment increases. 
THE FACTORS ASSOCIATED WITH RECURRENCE OF THE 
DISEASE: (8,9,14) 
x Extensive disease 
x Cavitations 
x Severe lung lesion 
x HIV 
x Alcoholism  
x Diabetes mellitus  
x Male 
x Smoker 
x Concomitant illness 
x Underweight 
x Irregular treatment 
x Illiteracy 
x Overcrowding in residence 
x Drug resistance 
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Sex and weight has not been found to be a significant factor in 
relapses in India. 
Whether DOTS is given as intermittent regimen or continuous 
regimen for patient to come to health care facility on a regular basis for 
a period of 6 months needs time, money and energy more so in difficult 
terrains where reaching a health care facility may be a problem. These 
factors affect the regularity of treatment a factor found to influence 
relapse of tuberculosis. 
Immunosuppressive illness like diabetes, HIV has increased the 
relapse of treated patients. Patients started on cancer chemotherapy, 
corticosteroids, immunomodulatory therapy, monoclonal antibodies all 
can decrease patients immunity and cause relapse of tuberculosis.  
Decrease in weight gain during the course of treatment is also 
associated with increased in relapse of tuberculosis. Weight gain of less 
than 5 % with treatment is associated with increased chance of relapse. 
Patient  who  get  infected  with  a  drug  resistant  strain  or  develop  
resistance during the course of treatment have an increased chance of 
treatment failure and relapse. Drug resistance to rifampicin during the 
start of treatment is associated with an increase in relapse of 
tuberculosis. 
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Patients who have taken treatment irregularly are twice at risk 
than who have taken treatment regularly to develop relapse. Smoking 
has been associated with a three percent chance of relapse than the 
general population. 
DRUG RESISTANT TB 
Resistance  to  rifampicin  and  isoniazid  is  called  MDR  TB.  
Resistance to rifampicin, isoniazid, a second line injectable and 
fluroquinlone is called XDR TB. 
Globally around 3 % of the newly diagnosed TB patients are 
MDR TB. In the retreatment group the figure is around 20.2 %.in some 
areas like the eastern Europe and central Asia the rates may be as high 
as  20%  in  the  CAT  I   and   more  than  50%  in  CAT  II.  There  is  an  
estimated 300000 cases of MDR in 2012 and half of these cases were 
reported from India, China and Russia. Extensively drug resistant 
tuberculosis has also been reported. 92 countries have so far reported the 
occurrence of XDR-TB. Among the MDR-TB 9.6% is found to be 
XDR-TB. In India 26% of pulmonary tuberculosis patients are found to 
be MDR-TB. 2.2 % of the newly diagnosed sputum positive patients 
were found to be MDR TB and 15% of retreatment patients in India is 
found to be MDR TB(2). 
31 
 
 
  
  
32 
METHODS TO DO DST 
3 methods are used in RNTCP to detect drug resistance. 
x The conventional solid egg based Lowenstein- Jensen media. 
x Liquid culture media MGIT 
x Rapid molecular diagnostic methods like Line probe assay and 
Xpert MTB/Rif 
The conventional Lowenstein Jensen media in which the 
organism is grown in a media that contains the drug and drug resistance 
is noted is called phenotypic DST. The advantage of phenotypic DST is 
that it is available for more ATT drugs. It is reliable in the case if INH, 
Rifampicin and streptomycin. It is less reliable in the case of 
Ethambutol. 
Molecular DST are methods in which the presence of gene 
mutations are noted. They are also genotypic DST. 
The advantages of molecular method are, 
x Speed of diagnosis 
x Standardised testing  
x Fewer requirements for laboratory bio safety. 
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But molecular methods are better to detect only rifampicin 
resistance and they are used less in other drug resistance detection. 
Time taken for reporting DST by various methods: 
x LJ media    - 84 days  
x MGIT         - 42 days,  
x  LPA           - 72 hours and 
x Xpert/Rif    - 2 hours.  
LINE PROBE ASSAY(LPA)  
It involves the following steps(45) 
1. DNA is extracted from M. tuberculosis isolates (indirect testing) 
or directly from clinical specimens (direct testing).  
2. Polymerase chain reaction (PCR) amplification of the resistance-
determining region of the gene under question is performed using 
biotinylated primers.  
3. Labeled PCR products are hybridized with specific 
oligonucleotide probes immobilized on a strip.  
4. Captured labeled hybrids are detected by colorimetric 
development, enabling detection of the presence of M. 
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tuberculosis complex, as well as the presence of wild-type and 
mutation probes for resistance.  
5. If a mutation is present in one of the target regions, the amplicon 
will not hybridize with the relevant probe. Mutations are therefore 
detected by lack of binding to wild-type probes, as well as by 
binding to specific probes for the most commonly occurring 
mutations. The post hybridization reaction leads to the 
development  of  coloured  bands  on  the  strip  at  the  site  of  probe  
binding.  
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STEPS IN DOING XPERT MTB/RIF 
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THE CHOICE OF METHOD TO BE USE IN DRUG 
SUSCEPTIBILITY TESTING(46) 
MDR Diagnostic Technology Choice 
Molecular DST First 
Liquid culture isolation and LPA DST Second 
Solid culture isolation and LPA DST Third 
Liquid culture isolation and DST Fourth 
Solid culture isolation and DST Fifth 
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TREATMENT OF MDR TB & XDR TB 
 
Regimens to be used in the treatment of MDR and XDR TB are 
given in RNTCP guidelines. The drugs used in the treatment of drug 
resistant TB are grouped in to five groups based on the drug class, their 
efficacy in the treatment of tuberculosis and the experience in using 
these drugs in the treatment of tuberculosis. 
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GROUPING OF ANTI-TB DRUGS 
Grouping Drugs  
Group 1: First-line oral anti-TB 
agents 
Isoniazid (H); Rifampicin (R); 
Ethambutol (E); Pyrazinamide (Z) 
 
Group 2: Injectable anti-TB 
agents 
Streptomycin (S); Kanamycin 
(Km); Amikacin (Am); 
Capreomycin (Cm); Viomycin 
(Vm). 
 
Group 3: Fluoroquinolones Ciprofloxacin (Cfx); Ofloxacin 
(Ofx); Levofloxacin (Lvx); 
Moxifloxacin (Mfx); Gatifloxacin 
(Gfx) 
 
Group 4: Oral second-line anti-
TB agents 
Ethionamide (Eto); Prothionamide 
(Pto); Cycloserine (Cs); 
Terizadone (Trd); para-
aminosalicylic acid (PAS) 
 
Group 5: Agents with unclear 
efficacy (not 
recommended by WHO for 
routine use in 
MDR-TB patients) 
Clofazimine (Cfz); Linezolid (Lzd); 
Amoxicillin/Clavulanate 
(Amx/Clv); thioacetazone (Thz); 
imipenem/cilastatin (Ipm/Cln); 
high-dose isoniazid (high-dose H); 
Clarithromycin (Clr) 
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RNTCP recommends uniform regimen in the treatment of drug 
resistant tuberculosis but treatment is complicated by the following 
factors, 
x Presence of drug resistance to one of the second line drugs at the 
baseline. (Eg) Resistance to fluroquinolone. 
x Drug intolerance and treatment discontinuation is more common 
with the drug resistant regimen. 
Poor response to treatment with the second line regimen should 
alert the clinician to look for other causes of poor response like drug 
compliance, further development of drug resistance. 
MDR  TB  patient  should  be  started  on  initial  MDR  regimen  and  
should be subjected to DST during the course of treatment as and when 
indicated. The indications for second line DST are  
x Persistent culture or smear positive at six months of treatment 
x Culture or smear reversal during the course of treatment. 
It is preferred to have DST to the second line drugs during the 
start of treatment. But the problem is the availability of facilities to do 
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DST to second line drugs. So in places where base line second line DST 
cannot be done it is better not done.  
If  a  patient  started  on  the  MDR  TB  regimen  remains  culture  
positive at the end of six months the intensive phase is extended by one 
month at a time and the culture is repeated. Extension can be done three 
times so that the maximum period of intensive phase is 9 months. While 
repeating the culture to rule out XDR TB sensitivity is seen for 
kanamycin and ofloxacin if facilities permit capreomycin sensitivity is 
also seen. 
MDR TB REGIMEN 
In the intensive phase 6 drugs are used. In the continuation phase 
4 drugs are used. Intensive phase is for 6-9 months and the continuation 
phase is for 18 months. 
x Drugs used in the intensive phase are kanamycin, levofloxacin, 
ethionamide, cycloserine, ethambutaol and pyrazinamide. 
x Drugs used in the continuation phase are Levofloxacin, 
Ethionamide, Ethambutol and Cycloserine 
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CHANGES MADE IN REGIMEN IN SOME SPECIAL SITUATIONS 
ARE: 
x If patient is intolerant to kanamycin it is replaced by capreomycin  
if injectable option is not feasible then PAS is given. 
x If any oral second line drug intolerance is present then PAS is 
used. 
x Capreomycin is used in place of kanamycin if baseline resistance 
is present to kanamycin 
x If drug resistance to ofloxacin is present at the base line then a 
combination of moxifloxacin with PAS should be used in place of 
levofloxacin. 
x Baseline resistance to both kanamycin and capreomycin needs 
patient evaluation and treatment for XDR TB 
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INTEGRETED ALGORITHM FOR DR-TB TREATMENT 
`` 
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MDR  regimen  drugs  are  given  as  single  daily  dose.  Drugs  are  
given supervised for 6 days of a week. It is given unsupervised for 1 day 
in a week (Sunday). Injection is avoided on Sunday only oral drugs are 
given. Pyridoxine is given to all patients in MDR regimen. 
REGIMEN FOR MDR TB DOSAGE AND WEIGHT BAND 
RECOMMENDATIONS 
S.No. Drugs 16-25 Kgs 26-45 Kgs 46-70 Kgs 
1 Kanamycin 500 mg 500 mg 750 mg 
2 Levofloxacin 250 mg 750 mg 1000 mg 
3 Ethionamide 375 mg 500 mg 750 mg 
4 Ethambutol 400 mg 800 mg 1200 mg 
5 Pyrazinamide 500 mg 1250 mg 1500 mg 
6 Cycloserine 250 mg 500 mg 750 mg 
7 Pyridoxine 50 mg 100mg 100mg 
 
If  a  patient  gains  5  kg  or  more  during  treatment  he  can  be  
switched over to the next weight band. If he loses weight more than 5 kg 
he can be shifted to another weight band. The change in band group can 
be done when the next supply of drugs comes not necessarily once the 
patient has gained weight.  
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REGIMEN FOR XDR TB 
The intensive phase is for 6 to 12 months. It consists of 7 drugs . 
Capreomycin , PAS, moxifloxacin, high dose INH, clofazimine, 
linezolid, amoxicillin with clavulanic acid.  
x The continuation phase is for 18 months and it has six drugs. 
They are 
PAS, moxifloxacin, high dose INH, clofazimine, linezolid, 
amoxicillin with clavulanic acid. 
Similar to MDR TB treatment it is 6 days supervised treatment 
with one day of unsupervised treatment. 
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REGIMEN FOR XDR TB DOSAGE AND WEIGHT BAND 
RECOMMENDATIONS DRUGS 
Drugs  Dosage/day 
45 kg or less >45 Kg 
Capreomycin 750 mg  1000 mg 
PAS 10 mg 12mg 
Moxifloxacin 400 mg 400 mg 
High Dose INH 600 mg 600 mg 
Clofazimine 200mg 200 mg 
Linezolid 600 mg 600 mg 
Amoxyclav 875/125 mg 875/125 mg 
Pyridoxine 100 mg 100 mg 
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Algorithm for patients on MDR/XDR regimen who have defaulted 
treatment and returned within 6 months.(ALGORITHM 2)  
 
 
 
 
 
47 
Management of Patient on MDR & XDR Regimen who Return for 
Treatment after 6 months (ALGORITHM 3) 
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MATERIALS AND METHODS 
 
INSTITUTIONAL EHICAL COMMITTEE APPROVAL 
Obtained 
PERIOD OF STUDY 
January 2013- August 2013. 
PLACE OF STUDY 
Stanley medical college and Zone I and Zone II in Chennai 
under RNTCP 
STUDY DESIGN 
Prospective Study 
SAMPLE SIZE 
49 patients were included in the study. 
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INCLUSION CRITERIA 
Patients who have enrolled for ATT under RNTCP during the 
period October 2011 to March 2012 and declared cured or those who 
have completed treatment are included in the study. 
EXCLUSION CRITERIA 
x Patients who are having 
¾ Human Immunodeficiency Viral infection, 
¾  renal failure  
¾ Malignancies 
¾  any other immunosuppressive illnesses  
x Patients who are known to have contact with MDR TB patients. 
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STUDY METHODOLOGY 
               Patients who have enrolled for ATT under category I as new 
smear positive during the last quarter of 2011 and first quarter of 2012 
and completed ATT or declared cured are selected. Two fresh spot 
sputum samples are taken for AFB stain and culture sensitivity.  A chest 
X Ray PA view will be done for all these patients to assess their present 
radiological status. Biochemical investigations like blood urea, sugar 
(random), serum creatinine, serum bilirubin will be done. Retro virus 
status of the individual will also be assessed. A questionnaire is 
administered to the patients to assess their present clinical status. An 
initial assessment of the patient will be made from the clinical 
assessment, radiological assessment and sputum smear status. Sputum 
smear is examined in Stanley medical college RNTCP department by 
immunofluorescenc microscopy. 
Sputum culture is done in LJ medium at National institute of 
research in tuberculosis. If sputum culture cannot be given on the same 
day of collection of specimen it is stored in cold storage device and 
given within 72 hours to the laboratory. 
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If the patient is found to be sputum smear negative the final 
assessment will be done with the sputum culture for AFB results. If any 
co morbid illness or risk factors are encountered a detailed assessment 
of the respective illness or risk factor will also be done. Those patients 
who are found to be smear positive for AFB will be initiated on category 
II ATT as per RNTCP norms. Those patients whose sputum cultures are 
positive will be subjected to sensitivity studies to assess the drug 
resistance if any and started on appropriate ATT. 
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OBSERVATIONS 
      
            49 patients were included in the study. Of the 49 patients sputum 
smear examination for AFB was positive for 2 patients and culture for 
mycobacterium tuberculosis was positive for 3 patients. 
AGE  
The mean age of male patients included in the study was 
41.45(S.D 16.30) and female patients was 36.36(S.D 14.40). 36 patients 
were under the age of 50 and 13 patients were 50 years and above. 
Table 1: Mean Age distribution of the patients 
Age Male Female 
Number of Observations 38 11 
Mean Age 41.45 36.36 
Standard Deviation 16.30 14.40 
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Table 2: Percentage of different Age groups 
Age Frequencies Percentage 
(11-20) 5 10 
21-30 10 20 
31-40 10 20 
41-50 10 20 
51-60 6 12 
61-70 6 12 
71-80 2 4 
Total 49 100 
 
Of  the  three  relapse  patients  two  patients  were  of  less  than  50  
years of age and 1 was more than 50 years of age. 
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Table 3: Age & Relapse 
Age in 
Years 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
<50 36 2 
0.7059 
0.0586 to 
8.5060 
0.7839 
50 13 1 
 
By conventional criteria the association between the TB relapse 
and age is considered to be not statistically significant since p > 0.05. 
GENDER  
Among the 49 patients 38 patients were male patients and 11 
patients were female patients. All the three patients who were 
bacteriologically active were male patients.    
CHART 2 
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Table 4: Gender Prevalence 
Gender Frequency Percentage 
Male 38 78 
Female 11 22 
Total 49 100 
 
TABLE 5: GENDER & RELAPSE 
Gender 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) 
P 
value 
Male 38 3 
2.2676 0.1088 to 47.2605 0.5972 
Female 11 0 
 
By conventional criteria the association between the TB relapse 
and gender is considered to be not statistically significant since p > 0.05. 
SYMPTOMS AT PRESENT 
29% of patients were symptomatic among the study group. 
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CHART 3 
 
Table 6: Patients Symptoms 
Symptoms Initial Symptoms Percentage 
Present 
Symptoms Percentage 
P 
value 
No Symptoms 2 4 35 71  
Cough 0 0 3 6 0.3198 
Cough with 
expectoration 39 80 9 18 0.0286 
Breathlessness 0 0 1 2 0.3198 
Haemoptysis 7 14 1 2 0.0001 
Pneumonia 1 2 0 0 0.0817 
Total 49 100 49 100  
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By conventional criteria the association between the appearance 
symptoms (cough with expectoration and haemoptysis) during regular 
ATT and presently after completion of treatment are considered to be 
statistically significant since p < 0.05.  
This indicates that there is a true difference among groups and the 
difference  is  significant.  In  simple  terms  symptoms  of  TB  occur  more  
frequently among patients before initiation of ATT in comparison to 
patients who have completed ATT. This difference is true and 
significant and has not occurred by chance.  
In contrast, we can conclude that ATT is effective in reducing the 
symptoms of tuberculosis, especially cough with expectoration and 
haemoptysis there is a 78% significant reduction in cough with 
expectoration and 86% significant reduction in haemoptysis. 
Table: 7 Patients with Fever  
Fever Frequency Percentage 
Fever+ 3 6 
Fever- 46 94 
Total  49 100 
58 
Table: 8 Fever & Relapse 
Fever 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) 
P 
value 
Fever+ 3 0 
1.7755 0.0756 to 41.7249 0.7215 
Fever- 46 3 
 
By conventional criteria the association between the TB relapse 
and appearance of fever is considered to be not statistically significant 
since p > 0.05. 
Table: 9 Patients with Loss of Appetite 
Loss of Appetite Frequency Percentage 
Present 4 8 
Absent 45 92 
Total 49 100 
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Table: 10 Relapse & Loss of Appetite 
Loss of 
Appetite 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
Present 4 0 
1.3492 0.0597 to 30.5080 0.8507 
Absent 45 3 
 
By conventional criteria the association between the TB relapse 
and loss of appetite is considered to be not statistically significant since 
p > 0.05. 
Table: 11 Patients with Loss of Weight 
Loss of weight Frequency Percentage 
Yes 4 8 
No 45 92 
Total 49 100 
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Table: 12 Relapse & Loss of Weight 
Loss 
of 
weight 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) 
P 
value 
Yes 3 0 
1.7755 0.0756 to 41.7249 0.7215 
No 46 3 
 
By conventional criteria the association between the TB relapse 
and loss of weight is considered to be not statistically significant since  
p > 0.05. 
ANTHROPOMETRY 
The mean weight of the male patients in the study was 57.11(S.D 
7.45) and for female patients it is 47.36(S.D 6.68). 
CHART 4 
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Table 13: Mean Weight of the Patients 
Weight in Kg Male Female 
Number of Observations 38 11 
Mean  57.11 47.36 
Standard Deviation 7.45 6.68 
 
Table 14: Weight & Relapse 
Weight 
in Kg 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
< 50 6 1 
4.100 
0.3126 to 
53.7735 
0.2826  50 43 2 
 
By conventional criteria the association between the TB relapse 
and weight is considered to be not statistically significant since p > 0.05. 
The mean height of the male patients included in the study was 
162.71(S.D 5.34) and female patients was 151.91(S.D4.95). Two 
patients with relapse were over 160 cm in height and one patient with 
relapse was under the height of 160 cm 
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Table 15: Height Distribution 
Height in cm Frequency Percentage 
141-150 6 12 
151-160 16 33 
161-170 26 53 
171-180 1 2 
Total 49 100 
 
Table 16: Mean Height of Patients 
Height in cm Male Female 
Number of Observations 38 11 
Mean  162.71 151.91 
Standard Deviation 5.34 4.95 
 
By conventional criteria the association between the TB relapse and 
height is considered to be not statistically significant since p > 0.05. 
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Table 17: Height & Relapse 
Height 
in cm 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
< 160 21 1 
0.6500 
0.0550 to 
7.6867 
0.7325 
 160 28 2 
  
Of the 49 patients only 7 were under weight. The entire relapse was 
found in the normal BMI group. 
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CHART 6 
 
 
Table 18: BMI Distribution 
BMI Frequency Percentage 
Underweight 7 14 
Normal 42 86 
Total 49 100 
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Table 19: Mean BMI of Patients 
BMI Male Female 
Number of Observations 38 11 
Mean  21.52 20.52 
Standard Deviation 2.23 2.71 
 
Table 20: BMI & Relapse 
BMI 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) 
P 
value 
Underweight 7 0 
0.7524 
0.0351 to 
16.1165 
0.8556 
Normal 42 3 
 
By conventional criteria the association between the TB relapse and 
BMI is considered to be not statistically significant since p > 0.05. 
DRUG RESISTANCE 
Two patients were sensitive to all the first line drugs. One patient 
had resistance to isoniazid and streptomycin 
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Table 21: Bacteriological Status 
Culture & DST Frequency Percentage 
No Growth 46 94 
Growth with Sensitive 1 2 
Growth with Resistance 2 4 
Total 49 100 
 
CHART 7 
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Table 22: Drug Resistance & Relapse 
DR 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) 
P 
value 
DR+ 1 1 
55.8000 1.7814 to 1747.8124 0.0221 
DR- 48 2 
 
By conventional criteria the association between TB relapse and Drug 
resistance is considered to be statistically significant since p < 0.05.  
Since the 95% CI of 1.7814 to 1747.8124 does not include 1.0, 
the increased odds (OR 55.8000) of drug resistance to anti tuberculosis 
drugs among patients TB relapse reaches statistical significance. This 
increase in odds of drug resistance among TB relapse patients is true 
and significant and has not occurred by chance.  
It means that the patients who have a relapse of TB infection have 
55.8 times the risk of developing drug resistance compared to patients 
who do not have relapse of Tab infection. 66.7% of the patients with TB 
relapse had Drug susceptible mycobacterium. 
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ALCOHOL STATUS 
CHART 8 
 
 
Table 23: Percentage of Alcoholics 
Alcohol Intake Frequency Percentage 
Non Alcoholic 44 90 
Alcoholic up to 10gm/day 1 2 
Alcoholic up to 20gm/day 2 4 
Alcoholic up to 30gm/day 0 0 
Alcoholic up to 40gm/day 2 4 
Total 49 100 
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Table 24: Alcohol & Relapse 
Alcohol 
Intake 
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
Alcoholic  5 0 
1.0779 
0.0489 to 
23.7807 
0.9621 Non 
Alcoholic 
44 3 
 
By conventional criteria the association between the TB relapse and 
alcohol intake is considered to be not statistically significant since p > 
0.05. 
SMOKING  
11 patients were smokers of them only one of them showed 
bacteriological activity. 
Table 25: Distribution of Smokers and Non Smokers 
Smoking Frequency Percentage 
Non Smoker 38 78 
Smoker upto 10 pack years 3 6 
Smoker upto 20 pack years 3 6 
Smoker upto 30 Pack years 4 8 
Smoker upto 40 pack years 1 2 
Total 49 100 
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CHART 10 
 
 
 
Table 26: Smoking & Relapse 
Smoking  
Number of 
Observations 
Relapse 
Odds 
ratio 
(95%CI) P value 
Smoker   10 1 
2.3125 
0.1862 to 
28.7185 
0.5142 
Non 
Smoker 
39 2 
 
By conventional criteria the association between the TB relapse and 
smoking is considered to be not statistically significant since p > 0.05. 
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PRE EXISTING LUNG DISEASES: 
3 patients had history of pre-existing lung disease. None of the 
relapse patients had any prior history of lung disease. 
Table 27: Lung Disease and Relapse 
Pre-
existing 
lung 
disease 
Number of 
Observations Relapse 
Odds 
ratio (95%CI) P value 
Disease+ 3 0 
1.7755 0.0756 to 41.7249 0.7215 
Disease- 46 3 
 
By conventional criteria the association between the TB relapse and pre-
existing lung disease is considered to be not statistically significant 
since p > 0.05. 
CHART 11 
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RESULTS 
1. The average age of the patients with relapse of TB is 44. 
2. The relapse of pulmonary TB among patients who have 
completed ATT under RNTCP is 6%(n=49)  
3. Patients with primary drug resistance may have more chance of 
relapse ( OR 55.8, CI 1.78 to 1747.81) 
4. The clinical manifestations are much less is patients with TB 
relapse (33% when in comparison 67% during ATT) 
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                                       DISCUSSION 
           
Sputum positive Pulmonary Tuberculosis patients treated under 
RNTCP in India show a cure rate of 88% (2). Relapse of the treated 
patients vary in different population varying between 0 to 14 % (9).  In 
International studies the relapse rate in culture based studies was found 
to be 3.6% (13),  but  in India the relapse rate is  high 10% (14). In present 
study the relapse rate was around 6%. In another study from South India 
the relapse rate was found to be 4.8% among the non smokers who have 
taken ATT regularly without evidence of drug resistance (12). 
Majority  of  the  patients  are  asymptomatic  at  present  (71%).  Of  
the symptomatic patients the most common symptom is productive 
cough followed by dry cough. Other symptoms with which the patients 
have presented are breathlessness and haemoptysis. Of the relapse 
patient’s only one patient was symptomatic. The constitutional 
symptoms present in the study group individual were fever, loss of 
appetite, loss of weight. None of the relapse patients had constitutional 
symptoms. The relapse patients usually present with less of clinical 
manifestations. 
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Statistical analysis of age, height and BMI of the current study 
population showed no difference in different groups of the study based 
on these parameters. Age and weight has been shown to be significant 
factors of relapse in various studies (12) but in the present study relapse 
was not associated with these factors 
Male gender has been associated with increased chance of 
relapse(9,12), which correlates with the present study where the relapse 
rate is found to be high in males (100%). This could be a selection bias 
since  78  %  of  the  study  population  were  males  and  only  22%  were  
females. The difference may also be because of the increased prevalence 
of tuberculosis of tuberculosis in male (2), increased access of males to 
health care facility. In India the male to female ratio of notification of 
tuberculosis is high (2.2) compared to the global ratio of 1.9. 
20% of relapse was associated with MDR TB in previous 
studies(2).  In the current study no relapse patient was found to have 
MDR TB. Two patients of the current study had isolates that were 
sensitive to all first line drugs. One patient had resistance to isoniazid 
and streptomycin. His sputum AFB isolate was sensitive to rifampicin 
and hence could not be classified as MDR TB. In fully intermittent 
therapy in Indian context initial INH resistance is expected to be 20-
25% under programme conditions (41). In daily regimen the chance of 
75 
INH resistance is 8%(40).  In  patients  who  come  for  retreatment  the  
presence of INH resistance ranges from 47.7% to 87.1% (44). 
In the present study relapse was not associated with diabetes 
mellitus. In previous studies diabetes was associated with an increased 
risk of relapse of tuberculosis (31). Diabetes mellitus is also associated 
with an increased risk of severe disease and retreatment. 
In the present study alcohol was not associated with an increased 
risk  of  relapse.  But  in  previous  studies  alcohol  was  found  to  be  
associated with increased chance of relapse (12). 
In the present study relapse rate that was found after one year of 
completion of ATT was 6%. The relapse rate that is acceptable on 
follow up of sputum positive pulmonary tuberculosis patients is< 5 
%(39). Most of the relapse has been found to occur in 6 to 12 months 
after  completion  of  ATT.  In  RNTCP  patients  are  not  followed  up  
following treatment completion for relapse. Many patients who relapse, 
fail or default do not return to the programme(15).  There is  a  paucity of  
data on the long term outcomes with the regimens given in the RNTCP. 
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LIMITATIONS OF THE STUDY 
                          
¾ Small sample size 
¾ Use of spot sputum specimen  
¾ Radiographic evaluation which was in the initial protocol was not 
done during the study period 
¾ Non randomized method of sampling 
¾ There may be a male bias in the selection of cases in the study 
¾  The study did not differentiate between relapse relapse due to 
reinfection from relapse due to endogenous reactivation 
 
 
  
77 
CONCLUSIONS 
 
1. Clinicians should impressed about the probability of  relapse of 
TB within the first year of completion of ATT.  
2. Sputum re-evaluation at regular intervals starting 3 months after 
completion of treatment should be performed especially among 
high risk patients with co morbidities and HIV. 
3. The relapse rate under the DOTS programme can be reduced by 
ensuring that patients take their treatment regularly and are 
counselled effectively about drug resistance. 
4. Evaluation of primary resistance prior to treatment may help in 
avoiding future relapses. 
5. Early patient retrieval mechanism should be implemented 
effectively to maintain regularity in TB treatment. This will 
prevent relapse and drug resistance. 
6. The combination of both the relapse in TB and increased 
development of drug resistant Mycobacterium potentially carries 
a risk of global spreading, with serious implications for TB 
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control and the achievement of the United Nations Millennium 
Development Goals. 
7. Given the growing epidemic of DM worldwide, it is necessary to 
add  DM  prevention  and  control  strategies  to  TB  control  
programmes and vice versa and to evaluate their effectiveness. 
The combination of both diseases potentially carries a risk of 
global spreading, with serious implications for TB control and the 
achievement of the United Nations Millennium Development 
Goals. 
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 PROFORMA 
 
S.No                                                                   Date   
Name                                                                  Age                    Sex 
TB No                                                                Zone                  DOTS site 
Height                                                                Weight 
      
RBS                mg/dl 
Urea                mg/dl 
Creatinine                mg/dl 
 
 
 
 
HIV I & II 
 
CXR-PA view 
 
 
Sputum AFB:                                                                    Sputum culture: 
 
 
If Culture positive DST  
INH 
Rifampicin 
 
 
 
T.Bilirubin                     
mg/dl 
SGOT                     
IU/L 
SGPT                     
IU/L 
ALP                     
IU/L 
T.Protein                     g/dl 
Albumin                      g/dl 
 QUESTIONNAIRE 
 
Symptom for which pulmonary TB was diagnosed 
 
Symptom at present 
 
Fever 
LOA 
LOA    
Anti Tuberculosis Treatment: 
Started  
Completed  
Duration  
Regularity  
Outcome  
 
Contact with MDR patient 
DM 
                          Treatment regular/ Irregular 
HIV 
Pre-existing lung disease 
Renal disease 
Chronic liver disease 
 
Alcohol                                  
g/wk 
 
Smoking                                pack years 
 
Type   Duration   
Amount    No.of days /wk  
  
 
 
 
 
 
